 |
|
MoxalactamEvaluation of Clinical Bleeding in Patients With Abdominal Infection
Raymond J. Joehl, MD;
Dennis A. Rasbach, MD;
James O. Ballard, MD;
Michael R. Weitekamp, MD;
Fred R. Sattler, MD
Arch Surg. 1983;118(11):1259-1261.
Abstract
• Previous clinical studies have emphasized that hypoprothrombinemia may occur during treatment with moxalactam disodium, a new broad-spectrum cephalosporin. Usually, this abnormality is corrected by administering vitamin K. Recent case reports have described bleeding complications associated with moxalactam therapy and suggested that platelet function is depressed by this drug. We studied eight patients with abdominal infection who were treated with moxalactam. Six of them had prolonged template bleeding times, and two had clinically significant hemorrhage (epistaxis, hematuria, and rectal bleeding) during treatment with moxalactam. These observations suggest that coagulation studies and template bleeding times should be monitored during moxalactam therapy, especially before major surgery.
(Arch Surg 1983;118:1259-1261)
Author Affiliations
From the Department of Surgery, Division of General Surgery (Drs Joehl and Rasbach) and Department of Medicine, Divisions of Hematology (Dr Ballard) and Infectious Disease (Drs Weitekamp and Sattler), Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey.
Footnotes
Accepted for publication July 5, 1983.
Reprint requests to Department of Surgery, Milton S. Hershey Medical Center, Pennsylvania State University, PO Box 850, Hershey, PA 17033 (Dr Joehl).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Moxalactam vs Tobramycin-Clindamycin: A Randomized Trial in Secondary Peritonitis
Stellato et al.
Arch Surg 1988;123:714-717.
ABSTRACT
Potential for Bleeding with the New Beta-Lactam Antibiotics
SATTLER et al.
ANN INTERN MED 1986;105:924-931.
ABSTRACT
|
